Exhibit D — the fair bit
The steak under the parsley.
Strip away the jokes and there is a real, technically credible niche hardware company here: government-supported R&D, actual medical-water products, regulatory credentials and apparently meaningful institutional deployments. This roast never concluded “there's nothing here.” Quite the opposite. The problem is that the public positioning appears materially less mature than the underlying company.
The 8 structural weaknesses
Technology inflation
Ordinary remote monitoring is marketed with “predictive” language, without enough published evidence of genuinely predictive technology.
Unsupported comparative claims
“20% more efficiency” and “50% lower CAPEX & OPEX” lack adequate disclosed methodology.
Weak proof architecture
Surprisingly little visible customer evidence, case studies, deployment statistics or quantified field performance on the homepage.
Award dependence
2019–2021 recognitions remain central to the story in 2026.
Confused innovation narrative
Licensed CSIR technology, company patent(s), regulatory approvals and proprietary innovation are not cleanly separated.
Thin IoT differentiation
Based on disclosed functionality, the connected layer looks like conventional telemetry and dashboarding rather than proprietary deep tech.
Brand scope exceeds product scope
“Healthcare innovation” and heart-health monitoring sit on top of a currently water-centric public catalogue.
Hidden commercial credibility
Apparently strong institutional installation claims exist in court records — and are barely leveraged on the company website.
Where we have to give them credit
Actual substance detectedIronically, this is where the roast stalls. Government sources and court records substantiate important parts of Althion's technical history — which makes the website's badge-collection approach even more frustrating.
ISO 13485 certification for medical-device quality management (per Delhi HC records)
CDSCO Class C licence for the dialysis-grade RO device
DSIR-recognised in-house R&D centre
Indian Patent No. 379691 (granted 21 Oct 2021) for a compact softener-free hemodialysis RO system
CSIR-IICT licensed membrane technology — no resin softener, less salt, potential water & electricity savings
Listed by India's Department of Pharmaceuticals as a portable RO plant manufacturer
40+ claimed installations including AIIMS campuses, NIMS Hyderabad, CMC Vellore, Tata Memorial and Sir Ganga Ram Hospital (per counsel, Delhi HC 2026)
A company selling mission-critical water infrastructure for dialysis should radiate engineering evidence. Instead the site often radiates startup pitch competition finalist.
The turnaround roadmap — free of charge
Publish the math
Every comparative claim gets a methodology page, a baseline configuration and a five-year TCO model.
Rename 'predictive' to 'threshold alerts'
Until an actual model ships. Then publish the model card, training data summary and accuracy.
Move customers out of the courtroom
Referenceable logos, case studies and before/after numbers belong on the homepage, not in judgments.
Retire the 2019–2021 award hero
Lead with what shipped this quarter. Awards become a footer, not a headline.
Draw the IP map once
Licensed CSIR-IICT membrane IP vs. owned system patents — one clean diagram a buyer can read in ten seconds.
Sell the steak, not the parsley
Lead with softener-free, salt-saving, water-saving architecture. Let the SMS alerts be a footnote.
Final sign-off
“Althion spent nine years developing genuinely interesting medical-grade RO technology, then built a website that desperately tries to convince you the exciting part is that the RO can send an SMS.”
The company appears to have enough actual hardware and engineering substance that it doesn't need to cosplay as a software startup — yet its marketing repeatedly does exactly that. That is the biggest irony of Althion's public presence, and the entire reason this roast exists.
Back to the roasts